18-782 / S-023 rsp.

NDA 17-612/S-031
NDA 17-802/S-018
NDA 18-668/S-030
NDA 18-782/S-023

Wyeth Ayerst Laboratories
Attention: Jennifer W. Phillips, Pharm.D.
Director, Women's Health Care Products
World Wide Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299 Dear Ms. Phillips:

APR 3 2000

Please refer to your supplemental new drug applications dated December 12, 1996, received December 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for

Lo/Ovral Tablets (noregestrel/ethinyl estradiol), NDA 17-6 12;
Lo/Ovral-28 Tablets (noregestrel/ethinyl estradiol), NDA 17-802;
Nordette-21 Tablets (levonorgetsrel/ethinyl estradiol), NDA 18-668; and
Nordette-28 Tablets (levonorgetsrel/ethinyl estradiol), NDA 18-782.

We acknowledge receipt of your submission dated March 21, 2000. Your submission of March 21, 2000 constituted a complete response to our July 31, 1997 action letter.

We also refer to our March 4, 1998 letter requesting the addition of a pediatric use statement. These supplemental new drug applications provide for the following changes to the label:

INDICATIONS and USAGE section

Updated Trussel Table to the 1998 table in the prescribing information, and include results with the contraceptive sponge and the female condom.

PRECAUTIONS section

Pediatric Use subsection

"Safety and efficacy of **Tradename** have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated."

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted final printed labeling (package insert submitted March 21,2000, patient package insert submitted March 21, 2000). Accordingly, these supplemental applications are approved effective on the date of this letter.

We remind you, of your commitment, to reinstate the language, regarding the contraceptive sponge, to the instruction portion of the patient labeling in the next printing.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mockup form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MED WATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Jennifer Mercier, B.S., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Susan Allen, M.D., M.P.H.
Acting Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

TABLE:PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF A CONTRACEPTIVE METHOD

Method	Perfect Use	Average Use
Levonorgestrel implants	0.05	0.05
Male sterilization	0.10	0.15
Female sterilization	0.50	0.50
Depo-Provera® (injectable progestogen)	0.30	0.30
Oral contraceptives		5
Combined	0.10	NA
Progestin only	0.50	NA
IUD		
Progesterone	1.50	2.00
Copper T 380A	0.60	0.80
Condom (male) without spermicide	3	14
(female) without spermicide	5	21
Cervical cap		
Never given birth	9	20
Given birth	26	40
Vaginal Sponge		
Never given birth	9	20
Given birth	20	40
Diaphragm with spermicidal cream or jelly	6	20
Spermicides alone (foam, creams, jellies, and vaginal suppositories)	6	26
Periodic abstinence (all methods)	1-9*	25
Withdrawal	4	19
No contraception (planned pregnancy)	85	85

NA -not available

*Depending on method (calender, ovulation symptothermal, post-ovulation

Adapted from Hatcher RA et al, *Contraceptive Technology: 17th Revised Edition.* NY,NY: Ardent Medi, Inc, 1998

WYETH-AYERST RESEARCH AJ 10/6/97 ORIGINAL

P.O. BOX 8299, PHILADELPHIA, PA 19101-8299 • (610) 902-3710
FAX: (610) 964-5973

Division of American Home Products Corporation

U.S. REGULATORY AFFAIRS

/S/ 10/1/97

No. 16-672/S-046 No. 16-806/S-028
No. 17-612/S-031 No. 17-802/S-018
No. 18-668/S-030 No. 18-782/S-023

SUPPL NEW CORRESP

/S/ 10-1-97

September 24, 1997

SLR-023 SNC



Lisa D. Rarick, M.D., Director
Division of Reproductive and Urologic Drug Products (HFD-580)
Room 17B-20
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. Rarick:

Reference is made to our approved New Drug Applications and supplemental applications listed below. Reference is also made to FDA's letter dated July 31, 1997 received by Wyeth-Ayerst Research August 4, 1997 which found these supplemental applications to be approvable.

No. 16-672	Ovral *(norgestrel and ethinyl estradiol)* Tablets	S-046
No. 16-806	Ovral-28 *(norgestrel and ethinyl estradiol)* Tablets	S-028
No. 17-612	Lo/Ovral *(norgestrel and ethinyl estradiol)* Tablets	S-031
No. 17-802	Lo/Ovral-28 *(norgestrel and ethinyl estradiol)* Tablets	S-018
No. 18-668	Nordette-21 *(levonorgestrel and ethinyl estradiol)* Tablets	S-030
No. 18-782	Nordette-28 *(levonorgestrel and ethinyl estradiol)* Tablets	S-023

The purpose of this letter is to notify the Agency of our intent to amend these supplemental applications in response to your July 31, 1997 letter, in accordance with 21 CRF 314.120(a)(1).



Sincerely,
Wyeth-Ayerst Laboratories

Joan E Barton

Joan E. Barton, Associate Director
Women's Health Care Products
U.S. Drug Regulatory Affairs

LTH-138D

ORIGINAL FEB 25 1997

NDA 16-672 NDA 18-206 NDA 19-190
NDA 16-806 NDA 18-782
NDA 17-612 NDA 18-668
NDA 17-802 NDA 19-192

Wyeth-Ayerst Laboratories
Attention: Ms. Joan Barton
Manager, Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-1245

Dear Ms. Barton:

Reference is made to your approved new drug applications submitted pursuant to section 505(b) of the Federal Food, Drug and Cosmetic Act for the following preparations:

Ovral (norgestrel and ethinyl estradiol) Tablets	(NDA 16-672);
Ovral-28 (norgestrel and ethinyl estradiol) Tablets	(NDA 16-806);
Lo/Ovral (norgestrel and ethinyl estradiol) Tablets	(NDA 17-612);
Lo/Ovral-28 (norgestrel and ethinyl estradiol) Tablets	(NDA 17-802);
Lo/Ovral and Ferrous Fumarate (norgestrel and ethinyl estradiol tablets and ferrous fumarate tablets)	(NDA 18-206);
Nordette-21 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-668);
Nordette-28 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-782);
Triphasil-21 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 19-192); and
Triphasil 28 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 19-190).

Additional reference is made to the following products of yours, distributed by Berlex:

Levlen-21 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-668);
Levlen-28 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-782);
Tri-Levlen-21 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 19-192); and
Tri-Levlen-28 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 19-190).

The Commissioner for Food and Drugs, in the enclosed Federal Register notice published on February 25, 1997, has concluded that certain combined oral contraceptives containing ethinyl estradiol and norgestrel or levonorgestrel are safe and effective for use as postcoital emergency contraception. Your products listed in the appendix to the notice are products the Agency has found suitable for this use. We would welcome the submission of supplemental NDAs for this indication.

As stated in the notice, the safety and effectiveness requirements of 21 CFR 314.50 may be met by citing the published literature listed in the References section of the notice. We would be happy to work with you in preparing the supplements.

Should you have any questions, please contact Christina Kish at (301) 827-4260.

Sincerely,

/S/

Lisa Rarick, M.D.
Director
Division of Reproductive and Urologic
Drug Products (HFD-580)
Office Of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE

cc:
Orig. NDA's (9)
HFD-580/PPrice
HFD-580/HJolson/LPauls
HF-004/MPendergast
HFD-005/JAxelrad/CRogers
HFD-580/CKish/2.18.97/n16672ecr.sr
concurrences:LPauls 2.24.97/LRarick 2.24.97/JAxelrad 2.21.97

SUPPLEMENT REQUEST

APPEARS THIS WAY
ON ORIGINAL

ORIGINAL

JUL 31 1997

NDA 16-672/S-046 NDA 17-802/S-018
NDA 16-806/S-028 NDA 18-668/S-030
NDA 17-612/S-031 NDA 18-782/S-023

Wyeth-Ayerst Laboratories
Attention: Ms. Joan E. Barton
Associate Director, Marketed Products
Drug Regulatory Affairs
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Barton:

Please refer to your supplemental new drug applications dated December 12, 1996, received December 17, 1996, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act and the provisions of 21 CFR 314.70 (c) for:

Ovral (norgestrel and ethinyl estradiol) Tablets	(NDA 16-672);
Ovral-28 (norgestrel and ethinyl estradiol) Tablets	(NDA 16-806);
Lo/Ovral (norgestrel and ethinyl estradiol) Tablets	(NDA 17-612);
Lo/Ovral-28 (norgestrel and ethinyl estradiol) Tablets	(NDA 17-802);
Nordette-21 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-668); and
Nordette-28 (levonorgestrel and ethinyl estradiol) Tablets	(NDA 18-782).

These supplemental applications provide for a revision of the **EFFECTIVENESS OF ORAL CONTRACEPTIVES SECTION** of the Detailed Patient Package Insert and the Prescribing information, specifically to delete all reference to the contraceptive sponge and to clarify DMPA to "Depo-Provera" and condom to "male condom."

We have completed the review of these supplemental applications as submitted with final printed labeling (FPL), and they are approvable. Before these applications may be approved, however, it will be necessary for you to revise the labeling as follows:

1. The Trussell Table (figure 1) in the Prescribing information must be updated to the 1998 table (enclosed for your reference), and include results with the contraceptive sponge and the female condom.

2. All references to the contraceptive sponge that were deleted must be reinstated.

Please submit 20 copies of the Final printed labeling (FPL) to each application, ten of which are individually mounted on heavy-weight paper or similar material.

If additional information relating to the safety or effectiveness of these drugs becomes available, revision of the labeling may be required.

Within 10 days after the date of this letter, you are required to amend the supplemental applications, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of such action FDA may take action to withdraw the applications.

These changes may not be implemented until you have been notified in writing that these supplemental applications are approved.

If you have any questions, please contact Christina Kish, Consumer Safety Officer, at (301) 827-4260.

Sincerely,

/S/ 7-30-97

Lisa D. Rarick, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE

cc:
Orig. NDA's (6)
HFD-580
HFD-92/DDM-DIAB
HFD-40/DDMAC
DISTRICT OFFICE
HFD-580/PPrice/HJolson/LRarick
HFD-580/CKish/7.24.97/n16672ap.s46
concurrence:LPauls 7.25.97/PPrice 7.28.97/HJolson 7.29.97

SUPPLEMENT APPROVABLE (S/AE)

APPEARS THIS WAY
ON ORIGINAL

ORIGINAL

Medical Officer's Summary of NDA Supplements JUL 23 1997

NDA 16-627/S046
NDA 17-802/S018
NDA 16-806/S028
NDA 18-668/S030
NDA 17-612/S031
NDA 18-782/S023

Name of Drugs: Wyeth's Oral Contraceptive Products

Sponsor: Wyeth-Ayerst

Material Reviewed: Labeling supplements

Date of Correspondence: December 12, 1996

Comments:
This labeling has previously been reviewed in detail by the CSO, Christina Kish, and changes made to the PI and PPI have been noted by her. Important changes to the sponsor's label are:

1. The sponge has been deleted from table 1, which is the lowest and expected rates during the first year of continuous use of a contraceptive method. Although, the sponge is currently not marketed in the US, an approved NDA still exist. Therefore, the sponge should be placed back into table 1.

2. Trussel's table, which is Table 1, should be updated to the pre-published 1998 table. Pregnancy rates are outdated in the 1990 and 1994 table.

3. Depo-provera is now spelled out, instead of DMPA. This is appropriate.

4. Condom has ~~be~~ been changed to "male condom." This is acceptable. Data from the "female condom" should also be inserted.

Two other minor changes were noted by Christina Kish. These minor editorial changes are acceptable.

Recommendation:
Draft labeling is acceptable with the incorporation of suggested changes to Table 1, including updating Table 1 to Trussel's 1994 table.

/S/

Phill H. Price, M.D.
July 21, 1997

Concur /S/ 7/23/97

NDA 16-627/S-046 + 3 more
CSO notes on labeling supplement

Phill, the following comments are my initial comparison of this labeling supplement, the last approved labeling supplement and the last approved FPL. Remember that you need to draft a Medical Officer review of the supplement, like you did for the last one.

The following changes have been made:

1. The sponge has been deleted from the detailed patient insert and the detailed patient labeling section of the physician insert. The Deletions occur both in the comparison of nonsurgical birth control methods, and in the instructions on how to take the pill where is was formerly used as an example of a backup barrier method. It is my understanding that — does not want the sponge deleted from the table, but the deletion from the how to take the pill section may be acceptable, ———

2. Also within the comparison of nonsurgical birth control methods Depo-Provera is named, it was formerly listed as DMPA with no brand name given, the condom is also now described as "male condom", it was formerly listed as "condom".

3. The Trussell table I believe needs to be updated. I think they are using the one from 1990. Some of the numbers are off.

4. The sponsor has added a storage statement to the How Supplied section. I think it's ok but we will need to run it by the Kasturi before we send out a letter.

5. The sponsor has added "and" to Table III so it now reads: "Annual number of birth-related deaths associated with control of fertility per 100,000 nonsterile women, by fertility-control method and according to age".

Everything else is the same.

Chris

APPEARS THIS WAY
ON ORIGINAL

USER FEE DATA ENTRY/VALIDATION FORM Ver.3(2/17/94)

NDA # 18-782 DOCUMENT ID/LETTER DATE SLR-023 Dec. 12, 1996

APPLICANT NAME Wyeth-Ayerst Labs.

PRODUCT NAME Nordette-28 tablets

FORM MUST BE COMPLETED ASAP

1. (YES) User Fee Cover Sheet Validated?

NOTE TO DOCUMENT ROOM:
PLEASE MAKE THE FOLLOWING CHANGES TO THE COMIS DATA ELEMENTS

2. YES (NO) **CLINICAL DATA?**
[Check YES if contains study reports or literature reports of what are explicitly or implicitly represented by the applicant to be adequate and well-controlled trials. "Clinical data do not include data used to modify the labelling to add a restriction that would improve the safe use of the drug (e.g., to add an adverse reaction, contraindication or warning to the labeling).]

REF **IF NO CLINICAL DATA IN SUBMISSION, INDICATE IF CLINICAL DATA ARE *CROSS REFERENCED* IN ANOTHER SUBMISSION?**

3. YES (NO) **NDA BEING SPLIT FOR ADMINISTRATIVE CONVENIENCE** (OTHER THAN BUNDLING)? IF YES, list ALL NDA numbers, review divisions & indicate those for which application fees apply.

NDA #	DIVISION		
N_____	_____	FEE	NO FEE
N_____	_____	FEE	NO FEE

4. (YES) NO **BUNDLING POLICY APPLIED CORRECTLY? NO DATA ENTRY REQUIRED FOR ELEMENT**
[Check YES if application is properly designated as one application or is properly submitted as a supplement instead of an original application. Check NO if application should be split into more than one application or submitted as an original instead of a supplement. IF NO, list resulting NDA numbers, and review divisions.]

NDA #	DIVISION	NDA #	DIVISION
N_____	_____	N_____	_____

5. P (S) **PRIORITY OR STANDARD?**

6. /S/ 12/19/96 **CSO SIGNATURE/DATE** /S/ **SCSO CONCURRENCE SIGNATURE/DATE**

COPY DISTRIBUTION: ORIGINAL TO ARCHIVAL AFTER DATA ENTRY, ONE COPY EACH TO DIVISION FILE AND CDER, ASSOCIATE DIRECTOR FOR POLICY HFD-5

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 18-782/S-023

Wyeth Laboratories
P.O. Box 8299
Philadelphia, PA 19101-8299

DEC 26 1996

Attention: Joan E. Barton
Associate Director, Marketed Products
Drug Regulatory Affairs

Dear Ms. Barton:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Nordette-28 (levonorgestrel and ethinly estrdiol)

NDA Number: 18-782

Supplement Number: S-023

Date of Supplement: December 12, 1996

Date of Receipt: December 17, 1996

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on February 15, 1997 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Reproductive and Urologic Drug Products, HFD-580
Office of Drug Evaluation II
Attention: Document Control Room 17B-20
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

/S/

Lana L. Pauls, M.P.H.
Chief, Project Management Staff
Division of Reproductive and Urologic
Drug Products, HFD-580
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:
Original NDA 18-782/S-023
HFD-580/Div. Files
HFD-580/CSO/Kish

SUPPLEMENT ACKNOWLEDGEMENT

AJ 8/6/97 ORIGINAL

Labeling SLR-025 SS

NDA No. 18-782 Rc'd. 12/17/96

Reviewed by:

WYETH-AYERST RESEARCH

P.O. BOX 8299, PHILADELPHIA, PA 19101-8299 • (610) 902-3710
FAX: (610)964-5973

Division of American Home Products Corporation

U.S. REGULATORY AFFAIRS

REVIEWS COMPLETED
CSO ACTION: ☒ LETTER ☐ N.A.I. ☐ MEMO
CSO INITIALS DATE

noted a completed Storage Statement
/S/ 8-5-97

NDA No. 16-672, 16-806, 17-612,
17-802, 18-668, 18-782

December 12, 1996

CENTER FOR DRUG EVALUATION AND RESEARCH
REC'D
DEC 17 1996
HFD-580

Lisa Rarick, M.D., Director
Division of Reproductive and Urologic Drug Products
Room 17B-20
Food and Drug Administration (HFD-580)
5600 Fishers Lane
Rockville, Maryland 20857

"SPECIAL SUPPLEMENT--Changes Being Effected"

Dear Dr. Rarick:

Reference is made to our approved New Drug Application Nos. 16-672, 16-806, 17-612, 17-802, 18-668 and 18-782 for Ovral® and Ovral®-28 Tablets (norgestrel and ethinyl estradiol tablets), Lo Ovral® and Lo Ovral®-28 Tablets (norgestrel and ethinyl estradiol tablets), and Nordette®-21 and Nordette®-28 Tablets (levonorgestrel and ethinyl estradiol tablets), respectively.

The purpose of this "Special Supplement--Changes Being Effected" is to provide final printed labeling for physician and detailed patient package inserts. This labeling has been revised to delete reference to the vaginal sponge in the detailed patient insert and the detailed patient labeling section of the physician insert because the vaginal sponge is no longer available. This deletion occurs under the "Effectiveness of Oral Contraceptives," and "How to Take the Pill" sections. Additionally, the reference to the condom under the "Effectiveness of Oral Contraceptives" section is clarified to specify the male condom. The storage statement "Store at room temperature, approx. 25° C (77° F)" has been added to the "How Supplied" section of the physician insert. This storage statement is consistent with that currently appearing on the product cartons. Finally, an editorial change was made to include the word "and" in Table III.

In support of this "Special Supplement--Changes Being Effected" provided herewith are 12 copies of final printed labeling for each package insert. One copy of each is highlighted for

the reviewers convenience showing the changes being made.

Should you have any questions concerning this information, please call the undersigned at (610) 902-3772 or Ms. Janice Barry at (610) 902-3784.

Sincerely yours,

WYETH-AYERST LABORATORIES

Joan E Barton

Joan E. Barton
Associate Director, Marketed Products
Drug Regulatory Affairs

jkb/fb/rarick

APPEARS THIS WAY
ON ORIGINAL

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG FOR HUMAN USE OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations 314)

Form Approved: OMB No. 0910-0001.
Expiration Date: December 31, 1995.
See OMB Statement on Page 3.

FOR FDA USE ONLY	
DATE RECEIVED	DATE FILED
DIVISION ASSIGNED	NDA/ANDA NO. ASS.

NOTE: No application may be filed unless a completed application form has been received *(21 CFR Part 314)*.

NAME OF APPLICANT Wyeth Laboratories	DATE OF SUBMISSION December 12, 1996
ADDRESS *(Number, Street, City, State and ZIP Code)* P.O. Box 8299 Philadelphia, PA 19101-8299	TELEPHONE NO. *(Include Area Code)* (610) 902-3772
	NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER *(If previously issued)* NDA No. 18-782

DRUG PRODUCT

ESTABLISHED NAME *(e.g., USP/USAN)*	PROPRIETARY NAME *(If any)*
Levonorgestrel and ethinyl estradiol	Nordette-28

CODE NAME *(If any)*	CHEMICAL NAME

DOSAGE FORM	ROUTE OF ADMINISTRATION	STRENGTHS(S)
tablets	oral	0.15mg levonorgestrel 0.03mg ethinyl estradiol

PROPOSED INDICATIONS FOR USE

prevention of pregnancy

LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS *(21 CFR Part 312)*, NEW DRUG OR ANTIBIOTIC APPLICATIONS *(21 CFR Part 314)*, AND DRUG MASTER FILES *(21 CFR 314.420)* REFERRED TO IN THIS APPLICATION:

INFORMATION ON APPLICATION

TYPE OF APPLICATION *(Check one)*

☒ THIS SUBMISSION IS A FULL APPLICATION *(21 CFR 314.50)* ☐ THIS SUBMISSION IS AN ABBREVIATED APPLICATION (ANDA) *(21 CFR 314.55)*

IF AN ANDA, IDENTIFY THE APPROVED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION

NAME OF DRUG	HOLDER OF APPROVED APPLICATION

TYPE SUBMISSION *(Check one)*

☐ PRESUBMISSION ☐ AN AMENDMENT TO A PENDING APPLICATION ☒ SUPPLEMENTAL APPLICATION
☐ ORIGINAL APPLICATION ☐ RESUBMISSION

SPECIFIC REGULATION(S) TO SUPPORT CHANGE OF APPLICATION *(e.g., Part 314.70(b)(2)(iv))* _____

PROPOSED MARKETING STATUS *(Check one)*

☒ APPLICATION FOR A PRESCRIPTION DRUG PRODUCT *(Rx)* ☐ APPLICATION FOR AN OVER-THE-COUNTER PRODUCT *(OTC)*

CONTENTS OF APPLICATION	
This application contains the following items: *(Check all that apply)*	
	1. Index
	2. Summary (21 CFR 314.50) (c))
	3. Chemistry, manufacturing, and control section (21 CFR 314.50 (d) (1))
	4. a. Samples (21 CFR 314.50 (e) (1)) (Submit only upon FDA's request)
	b. Methods Validation Package (21 CFR 314.50 (e) (2) (i))
	c. Labeling (21 CFR 314.50 (e) (2) (ii))
	i. draft labeling *(4 copies)*
X	ii. final printed labeling (12 copies)
	5. Nonclinical pharmacology and toxicology section (21 CFR 314.50 (d) (2))
	6. Human pharmacokinetics and bioavailability section (21 CFR 314.50 (d) (3))
	7. Microbiology section (21 CFR 314.50 (d) (4))
	8. Clinical data section (21 CFR 314.50 (d) (5))
	9. Safety update report (21 CFR 314.50 (d) (5) (vi) (b))
	10. Statistical section (21 CFR 314.50 (d) (6))
	11. Case report tabulations (21 CFR 314.50 (f) (1))
	12. Case reports forms (21 CFR 314.50 (f) (1))
	13. Patent information on any patent which claims the drug (21 U.S.C. 355 (b) or (c))
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C 355 (b) (2) or (j) (2) (A))
	15. OTHER *(Specify)*

I agree to update this application with new safety information about the drug that may reasonably affect the statement of contraindications, warnings, precautions, or adverse reactions in the draft labeling. I agree to submit these safety update reports as follows: (1) 4 months after the initial submission, (2) following receipt of an approvable letter and (3) at other times as requested by FDA. If this application is approved, I agree to comply with all laws and regulations that apply to approved applications, including the following:

1. Good manufacturing practice regulations in 21 CFR 210 and 211.
2. Labeling regulations in 21 CFR 201.
3. In the case of a prescription drug product, prescription drug advertising regulations in 21 CFR 202.
4. Regulations on making changes in application in 21 CFR 314.70, 314.71, and 314.72.
5. Regulations on reports in 21 CFR 314.80 and 314.81.
6. Local, state and Federal environmental impact laws.

If this application applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act I agree not to market the product until the Drug Enforcement Administration makes a final scheduling decision.

NAME OF RESPONSIBLE OFFICIAL OR AGENT	SIGNATURE OF RESPONSIBLE OFFICIAL OR AGENT	DATE
Joan E. Barton, Assoc. Director	Joan E Barton	12/12/96

ADDRESS *(Street, City, State, ZIP Code)*	TELEPHONE NO. *(Include Area Code)*
P.O. Box 8299 Philadelphia, PA 19101-8299	(610) 902-3772

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. *0910-0297*
Expiration Date: *November 30, 1996.*

USER FEE COVER SHEET

See Instructions on Reverse Before Completing This Form.

1. APPLICANT'S NAME AND ADDRESS
Wyeth Laboratories
P.O. Box 8299
Philadelphia, PA 19101-8299

2. USER FEE BILLING NAME, ADDRESS, AND CONTACT
Joseph Sonk, Ph.D.
Senior Director
Wyeth Laboratories
P.O. Box 8299
Philadelphia, PA 19101-8299

3. TELEPHONE NUMBER *(Include Area Code)*
(610) 902-3772

4. PRODUCT NAME
Nordette-28 Tablets

5. DOES THIS APPLICATION CONTAIN CLINICAL DATA? ☐ YES ☒ NO

IF YOUR RESPONSE IS "NO" AND THIS IS FOR A SUPPLEMENT, STOP HERE AND SIGN THIS FORM.

6. USER FEE I.D. NUMBER

7. LICENSE NUMBER/NDA NUMBER

8. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCLUSIONS? IF SO, CHECK THE APPLICABLE EXCLUSION.

☐ A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED BEFORE 9/1/92

☐ AN INSULIN PRODUCT SUBMITTED UNDER 506

☐ THE APPLICATION IS SUBMITTED UNDER 505(b)(2) *(See reverse before checking box.)*

FOR BIOLOGICAL PRODUCTS ONLY

☐ WHOLE BLOOD OR BLOOD COMPONENT FOR TRANSFUSION

☐ BOVINE BLOOD PRODUCT FOR TOPICAL APPLICATION LICENSED BEFORE 9/1/92

☐ A CRUDE ALLERGENIC EXTRACT PRODUCT

☐ AN "IN VITRO" DIAGNOSTIC BIOLOGIC PRODUCT LICENSED UNDER 351 OF THE PHS ACT

9. a. HAS THIS APPLICATION QUALIFIED FOR A SMALL BUSINESS EXCEPTION? ☐ YES *(See reverse if answered YES)* ☐ NO

b. HAS A WAIVER OF APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION? ☐ YES *(See reverse if answered YES)* ☐ NO

This completed form must be signed and accompany each new drug or biologic product, original or supplement.

SIGNATURE OF AUTHORIZED COMPANY REPRESENTATIVE	TITLE	DATE
Joan E. Barton *Joan E Barton*	Associate Director	December 12, 1996

FORM FDA 3397 (12/93)

INSTRUCTIONS FOR COMPLETING USER FEE COVER SHEET
FORM FDA 3397

Form FDA 3397 is to be completed for and submitted with each new drug or biologic product original application or supplement submitted to the Agency on or after January 1, 1994. The Prescription Drug User Fee Act of 1992, Public Law 102-571, authorizes the collection of the information requested on this form to implement the Act. Failure to complete this form may result in delay in processing of the submission.

ITEM NOS.	INSTRUCTIONS
1 - 3	Self-explanatory.
4	**PRODUCT NAME** - Include the generic name and the trade name, as applicable.
5	If clinical data are required for approval, then the application should be identified as containing clinical data. Please refer to the FDA policy regarding clinical data, Interim Guidance, Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees Under The Human Prescription Drug User Fee Act of 1992, July 12, 1993. Copies may be obtained from: Food and Drug Administration; Office of Small Business, Scientific and Trade Affairs; 5600 Fishers Lane, HF-50; Rockville, MD 20857. Please include two (2) pre-addressed mailing labels with your request.
6	**USER FEE I.D. NUMBER - PLEASE MAKE SURE THIS NUMBER AND THE NUMBER ON THE APPLICATION PAYMENT CHECK ARE THE SAME. FOR APPLICATIONS SUBJECT TO USER FEE PAYMENT**, please supply the following identifying information: **FOR DRUG PRODUCTS** - A unique identification number will be assigned to each submission. This individual identification number may be obtained by calling the Center for Drug Evaluation and Research Central Document Room, at (301) 443-8269. **FOR BIOLOGIC PRODUCTS** - The first 4 characters are the U.S. License Number, including leading zeros; the second characters are the product code (2 letters followed by 2 numbers); and the last 7 characters are the date on the cover letter of the submission, in the format: DDMONYR. If the facility is unlicensed, or the product code is unknown, a number can be obtained by calling the Center for Biologics Evaluation and Research, at (301) 594-2906. **EXAMPLE:** For U.S. License Number 4, product code ZZ01, with a document submission date of 8/3/93, the number would be: 0004ZZ0103AUG93.
7	**LICENSE NUMBER/NDA NUMBER** **FOR BIOLOGIC PRODUCTS** - Indicate the U.S. License Number. If the facility is unlicensed, leave this section blank. **FOR DRUG PRODUCTS** - Indicate the NDA number, if known, including a leading zero. NDA numbers can be obtained by calling the Center for Drug Evaluation and Research, Central Document Room, at (301) 443-0035. **EXAMPLE:** For NDA99999, the number would be: N099999.
8	**EXCLUSIONS** - Check the appropriate box if this application is NOT covered by user fees because it is excluded from the definition of "human drug application" as defined in Section 735(1) and (2) of the Prescription Drug User Fee Act. Section 505(b)(2) applications, as defined by the Federal Food, Drug, and Cosmetic Act, are excluded from application fees if: they are NOT for a new molecular entity which is an active ingredient (including any s or ester of an active ingredient); or NOT a new indication for use.
9	**WAIVER** - Complete this section only if the application has qualified for the small business exception or a waiver has been granted for user fees for this application. A copy of the official FDA notification that the waiver has been granted must be provided with this submission.